BRIEF — Allergan offloads rights to Trelstar

Ireland-headquartered drugmaker Allergan has pulled out of its commercialization deal with Debiopharm for Trelstar (triptorelin pamoate), a drug used in the USA to treat prostate cancer.

Switzerland-based Debiopharm is in advanced discussions with a potential partner in Canada and is engaged in a bidding process for US rights for the drug, for which it has developed three sustained-release formulations.

Thierry Mauvernay, president and delegate of the board for the family-owned group, said: “We are now looking for new partners with a strong footprint in urology to continue to bring Trelstar to the patients.”